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SUMMARY
Mutations in the CEBPA gene are present in 7%–10% of human patients with acute myeloid leukemia (AML).
However, no genetic models exist that demonstrate their etiological relevance. To mimic the most common
mutations affecting CEBPA—that is, those leading to loss of the 42 kDa C/EBPa isoform (p42) while retaining
the 30kDa isoform (p30)—we modified the mouse Cebpa locus to express only p30. p30 supported the
formation of granulocyte-macrophage progenitors. However, p42 was required for control of myeloid
progenitor proliferation, and p42-deficient mice developed AML with complete penetrance. p42-deficient
leukemia could be transferred by a Mac1+c-Kit+ population that gave rise only to myeloid cells in recipient
mice. Expression profiling of this population against normal Mac1+c-Kit+ progenitors revealed a signature
shared with MLL-AF9-transformed AML.INTRODUCTION
AML is a disease that has been found to reside in a self-renew-
ing population of cancer stem cells—that is, leukemia-initiating
cells (LICs). By transplantation of fractionated cells from patients
with AML into SCID mouse recipients, a population of
CD34+CD38 LICs were identified in patients with diverse AML
subtypes (Bonnet and Dick, 1997; Lapidot et al., 1994). These
cells, which may comprise only a small fraction of the tumor cells,
share surface markers with human repopulating hematopoietic
stem cells, and were found to give rise to the bulk of non-LIC tu-mor cells through a differentiation hierarchy analogous to that of
normal hematopoiesis. Recently, however, an alternative hy-
pothesis to the hematopoietic stem cell (HSC)-like LIC has
been developed. By transduction of mouse bone marrow (BM)
cells with oncogenic fusion proteins (MLL-ENL and MOZ-TIF2),
transformation of phenotypic HSCs, as well as committed mye-
loid progenitors (common myeloid progenitor [CMP] and granu-
locyte-macrophage progenitor [GMP]) has been achieved (Coz-
zio et al., 2003; Huntly et al., 2004; Somervaille and Cleary, 2006).
The resulting LICs display characteristics of committed myeloid
progenitors and give rise to nonleukemogenic progeny inSIGNIFICANCE
These results demonstrate that, in a mouse model, patient-derived CEBPA mutations are AML-initiating mutations, provid-
ing direct genetic validation of their etiological importance. Furthermore, we show that at the cellular level such mutations
uncouple myeloid lineage commitment from progenitor proliferation control, leading to the transformation of committed my-
eloid progenitor cells. Committed myeloid leukemia-initiating cells (LICs) have been derived in vitro through ectopic expres-
sion of translocation-derived oncogenic fusion proteins. We find that unbiased interrogation of the hematopoietic hierarchy
by an endogenous leukemia-initiating mutation can transform a committed AML-LIC and can identify a gene expression
profile shared between progenitors transformed by Cebpa mutation and MLL-AF9 overexpression, respectively, indicating
a conserved molecular basis for committed LIC transformation.Cancer Cell 13, 299–310, April 2008 ª2008 Elsevier Inc. 299
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AF9-transformed GMP-like LICs, the upregulation of a gene sub-
set normally restricted to HSCs was observed (Krivtsov et al.,
2006), raising the possibility that reactivation of an HSC-
associated self-renewal program is involved in the generation
of ectopically self-renewing progenitors. However, because
such myeloid-committed LICs have so far been generated only
through retroviral transduction and the resulting oncoprotein
overexpression, some key questions remain to be answered.
First, will the hematopoietic hierarchy, when interrogated by an
endogenous initiator mutation, generate such committed pro-
genitors? Second, because elements of the MLL-AF9 HSC-like
signature was present in human leukemias with MLL transloca-
tions, but not in non-MLL AML (Krivtsov et al., 2006), is reactiva-
tion of an HSC self-renewal program a general mechanism for
progenitor transformation, or do other self-renewal programs
exist that are able to maintain myeloid-committed LICs?
Mutations in the CEBPA gene, encoding the C/EBPa tran-
scription factor, are observed in 9% of de novo AML cases
and typically involve mutation of both CEBPA alleles (Nerlov,
2004). There is evidence that CEBPA mutations are early events
in the generation of leukemic clones, because, in the vast ma-
jority of cases, patients undergoing relapse of AML display the
same mutations in both CEBPA alleles as they did before
complete remission (Shih et al., 2006; Tiesmeier et al., 2003),
indicating that these mutations are present already in early leu-
kemic or preleukemic cell populations. In comparison, FLT3
mutation status is different in 30% of patients with AML
at the time of relapse, and mutations may be present in only
a subset of leukemic blasts, consistent with a role in disease
progression (Kottaridis et al., 2002; Shih et al., 2002). C/EBPa
is produced as two major polypeptides of 42 kDa (p42) and
30 kDa (p30), respectively, generated by alternative translation
initiation (Lin et al., 1993). The most common CEBPA mutation
found in patients with AML involves the selective loss of p42
expression due to frameshift mutations in the part of the coding
sequence unique to this isoform (Leroy et al., 2005), a mutation
also found in familial AML pedigrees (Sellick et al., 2005; Smith
et al., 2004).
Studies of C/EBPa knockout mice have demonstrated de-
fects in adipogenesis, granulopoiesis, and liver metabolism
(Wang et al., 1995; Zhang et al., 1997), the last of which leads
to perinatal lethality. More recently, a requirement for C/EBPa
in the formation of early bipotent GMPs from the CMP was
demonstrated (Heath et al., 2004; Zhang et al., 2004). These
studies did not show development of AML in the absence of
C/EBPa, most likely because of the early block in myeloid
lineage commitment. However, because those experiments
involve deletion of the entire C/EBPa coding sequence, they
do not accurately model CEBPA alleles found in patients,
where null mutations rarely, if ever, occur (Nerlov, 2004). To
more accurately model human AML-derived CEBPA mutations
and to determine the individual roles of p42 and p30 in GMP
formation, proliferation control, and myeloid tumor suppres-
sion, we generated knockin mice in which p42 translation is
specifically ablated. In the absence of p42, GMPs were still
formed; however, the resulting myeloid progenitors had vastly
increased self-renewal capacity, and mice uniformly pro-
gressed to AML and died with combined liver and bone mar-300 Cancer Cell 13, 299–310, April 2008 ª2008 Elsevier Inc.row failure. The disease could be transplanted in the absence
of detectable phenotypic HSCs but was efficiently transferred
by Mac1+c-Kit+ committed myeloid cells. Gene profiling of
p42-deficient LICs against normal Mac1+c-Kit+ cells identified
a gene expression signature overlapping that reported for
MLL-AF9-transformed GMPs but, to a lesser extent, containing
the self-renewal signature shared by HSCs and MLL-AF9-
transformed cells. These results show that (1) loss of p42
uncouples myeloid lineage commitment from progenitor prolif-
eration control, leading to myeloid lineage transformation; (2)
unbiased interrogation of the hematopoietic system by an
endogenous leukemia-initiating mutation may lead to the gen-
eration of committed myeloid LICs; and (3) committed progen-
itors transformed by distinct initiating mutations may share
a transformation-specific gene expression signature.
RESULTS
To disrupt translation of p42 from the mouse Cebpa gene, we
placed a LoxP-flanked neomycin resistance cassette site in the
Cebpa locus between the p42 and p30 initiation codons
(Figure 1A, LNLp30 allele). Upon Cre-mediated deletion of the
cassette, the remaining LoxP site introduced a nonsense codon
into the p42-specific part of the C/EBPa encoding open reading
frame (Lp30 allele), leading to termination of translation initiated
at the p42 AUG, without interfering with translation initiated at the
p30 AUG (Figure 1B). The LNLp30 allele was introduced into the
mouse Cebpa locus by homologous recombination in E14.1 ES
cells. Germline transmission was obtained from 2 independent
ES cell clones. By crossing mice carrying the LNLp30 allele to
the deleter-Cre line, mice heterozygous for the Lp30 allele
were obtained. These CebpaLp30/+ mice (henceforth ‘‘L/+
mice’’) displayed no obvious phenotype in hepatic, hematopoi-
etic, or adipose tissues, and both sexes were fertile. Intercrosses
between L/+ mice gave rise to homozygous L/L mice. However,
analysis of 17 litters showed that although +/+ (28/89) and L/+
mice (57/89) were observed at weaning at the expected Mende-
lian ratio of 1:2, only 4/89 mice with a L/L genotype were
retrieved, about 14% of the expected number. Immediately after
birth, the L/L genotype was observed at the Mendelian ratio
(Figure 1C), indicating significant perinatal lethality in the com-
plete absence of C/EBPa p42, but less severe than that resulting
from aCebpa null mutation (Wang et al., 1995). The phenotype of
newborn L/L mice was consistent with hypoglycemia being the
cause of perinatal death; however, the detailed metabolic
phenotype observed in the absence of p42 will be described
elsewhere (authors’ unpublished data). Specific loss of C/EBPa
p42 in L/L mice was confirmed by western blot analysis of liver
nuclear lysates (Figure 1D); this analysis also showed that in L/+
mice the p42/p30 ratio in the liver was decreased by 2.5 fold in
L/+ mice, relative to +/+ controls (Figure 1E). It is interesting to
note that disruption of p42 translation leads to an increase in
the level of p30; this is similar to what is observed in samples
from human patients with AML (Pabst et al., 2001). Surviving L/L
mice were observed to live for up to a year, and both sexes were
fertile. Thus, although C/EBPa p42 was required for efficient
perinatal survival, C/EBPa p30 is sufficient for sustaining fertile
life after the perinatal period.
Cancer Cell
Myeloid Tumor Suppression by C/EBPa p42Aberrant Granulopoiesis and Progression
to AML in Mice Lacking p42
AML mutations preventing p42 translation have been reported in
both the presence and absence of mutation of the second
CEBPA allele (Leroy et al., 2005; Nerlov, 2004). To determine
whetherCebpa alleles that are unable to translate p42 affect my-
eloid differentiation in the monoallelic state, we analyzed +/+ and
L/+ mice at various ages for symptoms of hematological malig-
nancy. L/+ mice were maintained for 18 months without mortality
or alterations in hematopoietic tissues or granulocyte differenti-
ation profile, compared with +/+ controls (see Figure S1 available
online). In contrast, L/L mice became anemic and moribund or
died after 9–14 months (Figure 2A). Necropsy revealed BM
failure, where normal hematopoietic cells were replaced by
Figure 1. Generation of p42 Knockout Mice
(A) Schematic representation of the targeting strategy used to generate the
Lp30 allele. The location of the ATG codons initiating p42 and p30, and the
epitope recognized by the anti-C/EBPa antibody, are shown.
(B) Western blot analysis of C/EBPa levels in total lysates of Q2bn cells
transiently transfected with pCMV-aLNLp30 (lane 1), pCMV-aWT (lane 2),
and pCMV-aLp30 (lane 3), respectively. The positions of the p42 and p30
are indicated.
(C) The percentage of pups retrieved from L/+ intercrosses with +/+, L/+, and
L/L genotypes at birth (P0; n = 28) and at weaning (P21; n = 89).
(D) Western blot analysis of C/EBPa-actin and b-actin levels in nuclear lysates
from livers of WT (lanes 1–2), L/+ (lanes 3–4), or L/L mice (lanes 5–6).
(E) Bar graph showing the levels of p42 (black bars) and p30 (gray bars),
respectively, normalized to b-actin levels. The levels were determined by
densitometric analysis of the western blots shown in (D). Numbers above the
bars show the p42/p30 ratio for the different genotypes.Mac-1+Gr-1lo cells with high myeloid blast count (>30%; Figures
2B and 2C). Spleens were highly enlarged (Figure 2D), and livers
contained massive hematopoietic infiltrates; the remaining
hepatocytes were few and scattered (Figure 2E). Immunohisto-
chemistry revealed myeloperoxidase (MPO) and NGal-positive
granulocytic cells infiltrating the tissue (Figure 2E, insets). This
analysis indicated that L/L mice uniformly developed AML, with
combined liver and BM failure as the likely cause of death.
Analysis of L/L mice before hematological collapse (<8
months) showed the presence of several age-dependent pheno-
types: in young mice (<2 months), a neutropenic BM (i.e., L/L-1
phenotype, low number of Mac1+Gr1+ cells [Figures 3A and
3D], normal level of c-Kit+ cells [Figure 3B], and few granulocytic
cells by morphology [Figure 3C]) was the most common obser-
vation. The peripheral blood also contained lower numbers of
myeloid cells Figure S4A). This phenotype uniformly progressed
to granulocyte lineage transformation by 6 months (L/L-3
phenotype; increase of c-Kit+ cells [Figures 3B and 3D] and
Figure 2. AML in the Absence of p42
(A) Kaplan-Meier plot showing latency to death or moribund state for the +/+,
L/+, and L/L genotypes. Significance of decreased survival of L/L mice versus
that of L/+ or +/+ mice is indicated.
(B) Staining of littermate control BM (L/+; upper panel) and BM from moribund
L/L mice (lower panel) using anti-Mac-1-FITC and anti-Gr-1-APC. Note the
accumulation of Mac-1+,Gr-1lo immature granulocytic cells in the L/L BM
(lower gate), whereas the normal granulocytes are Mac-1+,Gr-1hi (upper gate).
(C) Cytospin of BM from L/+ (left panel) and leukemic L/L (right panel) mice,
stained with May-Gru¨nwald-Giemsa. Scale bar, 10 mm.
(D) Spleens of L/L (top) and L/+ (bottom) mice at 30 weeks of age. Scale bar,
1 cm.
(E) Large frame: liver section of L/+ (left panels) and moribund L/L (right panels)
mice stained with hematoxylin-eosin. Insets: sections of the same liver stained
for MPO and NGal, respectively. Scale bars: main figure, 10 mm; left insets,
100 mm; and right insets, 200 mm.Cancer Cell 13, 299–310, April 2008 ª2008 Elsevier Inc. 301
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granulocyte differentiation [Figure 3C]), with granulocyte hyper-
proliferation (L/L-2 phenotype; high levels of Mac1+Gr1+ mature
Figure 3. Disease Progression of L/L Mice
(A) Number of Mac-1+Gr-1+ cells determined by flow cytometry performed on
bone marrow cells from control (L/+) mice and L/L mice characterized by
neutropenia (L/L-1 phenotype; n = 5), granulocyte hyperproliferation (L/L-2
phenotype; n = 4), and transformation (L/L-3 phenotype, n = 5), respectively.
Values significantly higher (*) and lower (#) than control values are indicated
(p < 0.05). Error bars = standard deviation (SD).
(B) Representation of c-Kit positive cells determined by flow cytometry
performed on the same bone marrow cells as in (A). Error bars = SD.
(C) Representation of different maturation stages of myeloid cells in bone
marrow from control (+/+, L/+; n = 6), L/L-1 (n = 5), L/L-2 (n = 4), and L/L-3
mice (n = 5), determined by differential counts performed on May-Gru¨nwald
Giemsa-stained cytospins. Values significantly higher (*) and lower (#) than
control values are indicated (p < 0.05). Error bars = SD.
(D) Distribution of the 3 L/L phenotypes in mice <2 months (n = 10), 2–6 months
(n = 7), and >6 months old (n = 12), respectively.
(E) Cytospin of splenocytes from L/+ and L/L-3 mice stained with May-Gru¨n-
wald -Giemsa. Scale bar, 20 mm.
(F) Analysis of myeloid cell proliferation in BM and spleen of L/+ and L/L-3
mice. Mice were injected intraperitoneally with BrdU 2 hr before death. Cells
were stained for expression of c-Kit and Mac-1, as well as for BrdU incorpora-
tion. The amount of BrdU-positive S-phase cells in the Mac-1c-Kithi,
Mac-1+c-Kithi, Mac-1hic-Kit+ and Mac-1hic-Kit fractions (top left to bottom
right) are indicated. ND: no BrdU staining detectable above the negative
control staining.302 Cancer Cell 13, 299–310, April 2008 ª2008 Elsevier Inc.granulocytes) as a possible intermediate stage (Figures 3C and
3D). Parallel changes in granulocyte numbers were observed in
the spleen (Figure S2). The differentiation profile of the erythroid
lineage was not altered (Figure S3); however, at late stages of
disease, normal hematopoiesis was displaced by malignant my-
eloid cells, leading to decreased hematocrit and leukocyte count
(Figures S4E–S4H). These results showed that loss of p42 leads
to myeloid lineage transformation. This phenotypic progression
is similar to that observed in mice containing a point mutation
in the C/EBPa basic region that disables C/EBPa-mediated
E2F repression and cell cycle control (BRM2 mice) (Porse
et al., 2005), with the important difference that L/L mice develop
malignant disease, whereas BRM2 mice do not. We therefore
focused on the malignant L/L-3 phenotype. In L/L-3 mice, the
spleen also contained high levels of myeloid blasts (Figure 2E),
indicative of ectopic myelopoiesis. We therefore analyzed the
presence of proliferating myeloid cells in BM and spleen of
L/L-3 and control L/+ mice by in vivo BrdU pulse-labeling. This
analysis showed that both L/L-3 BM and spleen contained
increased numbers of proliferating Mac-1+c-Kit+ cells, com-
pared with L/+ controls (Figure 3F). This was particularly signifi-
cant in the case of the spleen, because it normally contains
differentiated neutrophils and macrophages and few progeni-
tors. We did not observe any karyotypic abnormalities in tumor
cells from three leukemic mice, by use of spectral karyotyping
(SKY), with the exception of one case of loss of the Y chromo-
some (Figure S5). Loss of the Y chromosome is common in
human AML and does not have any detectable effect on progno-
sis (Wiktor et al., 2000). These results are consistent with the
observation that CEBPA mutant AML is most commonly karyo-
typically normal (Frohling et al., 2004).
Ectopic Proliferation and Increased Self-Renewal
of Myeloid Progenitors in the Absence of C/EBPa p42
It has previously been observed that deletion of the C/EBPa gene
leads to an increase in the proliferative capacity of progenitors
but that this increase does not lead to AML, most likely because
of the requirement for C/EBPa in myeloid lineage commitment at
the CMP-GMP transition (Heath et al., 2004; Zhang et al., 2004).
We therefore analyzed the presence of GMPs and the self-
renewal capacity of progenitors in mice lacking p42 before BM
transformation. GMPs were still formed in L/L-1 mice (Figure 4A),
showing that p30 is sufficient to mediate the CMP-GMP commit-
ment step. However, L/+ BM myeloid progenitors showed mildly
increased proliferative capacity, compared with +/+ progenitors,
and L/L-1 progenitors were highly proliferative with frequent
spontaneous immortalization (Figure 4B and data not shown).
The long-term myeloid cultures derived from L/L-1 mice con-
tained mainly Mac-1+c-Kit+ cells (Figure 4C), which were depen-
dent on stem cell factor (SCF) and interleukin (IL)-3 for survival
(Figure 4D). To determine whether the increased self-renewal
capacity was specifically present in committed myeloid cells, we
sorted LinSca-1+c-Kit+ (LSK) stem/pluripotent cells, GMPs,
and megakaryocyte-erythoid progenitor (MEP) populations
from L/L-1, L/+, and +/+ mice. MEPs generated only primary
colonies in all genotypes (Figure 4E), whereas L/L GMPs replated
over >5 passages, consistent with the data obtained with total
BM (Figure 4F). When LSK cells were replated, initial replating
efficiencies were similar in all genotypes. However, at the fourth
Cancer Cell
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(A) Analysis of myeloid progenitor populations in young (7 weeks) +/+, L/+, and
L/L-1 mice. The CMP, GMP, and MEP populations in BM were determined by
flow cytometry. The size of the CMP, GMP, and MEP populations is shown as
the percentage of total BM cells. These results are representative of three
determinations.
(B) Replating efficiency of myeloid progenitors from +/+ (n = 4), L/+ (n = 6), and
L/L-1 (n = 7) mice. Ten thousand BM cells were plated in M3434 medium, and
colonies counted after 1 week. The same number of cells was replated in
M3434 medium. This procedure was repeated six times. The average number
of colonies from triplicate cultures for each mouse is shown. An asterisk
(*) indicates a value significantly higher than the +/+ value (p < 0.05). Error
bars = SD.
(C) Immortalized L/L BM cells were stained with anti-c-Kit-APC and anti-Mac-
1-PE (lower panel) or corresponding isotype control antibodies (upper panel)
and were analyzed by flow cytometry. The percentage of cells in the four quad-
rants is indicated.
(D) Immortalized L/L BM cells were cultured in the presence of SCF, IL-3, and
IL-6 (complete medium), or in the absence of one of these factors, as indicated.
The number of live cells was counted at 3 day intervals, and the average of
three determinations is shown, normalized to the initial cell number (= 1).
(E) MEPs sorted from +/+, L/+, and L/L-1 mice (initial plating, 900 cells/dish)
were replated in M3434 medium as in (B). Error bars = SD.
(F) GMPs sorted from +/+, L/+, and L/L-1 mice (initial plating, 250 cells/dish)
were replated in M3434 medium as in (B). Error bars = SD.plating, the pattern from the GMP replating reemerged (L/+
mildly and L/L-1 strongly increased over +/+), indicating that
increased replating/self-renewal occurring once the pluripo-
tent/stem cells reach the committed myeloid progenitor stage
(Figure 4G). Indeed, cultures at this stage contained only
Mac1+ cells (data not shown). Before transformation, no change
in levels of LSK stem/pluripotent cells (Figure S6) or BM
myeloid progenitors (Figure 4A) was observed in L/L-1 BM,
compared with controls. However, after transformation (L/L-3
mice), the BM LSK compartment (Figure 4H) as well as the
committed myeloid CMP, GMP, and MEP populations (Fig-
ure 4I) were virtually absent. C/EBPa p30 is therefore sufficient
for commitment of CMPs to a myeloid fate, whereas p42 is
required to control the proliferation of myeloid progenitors. In
its absence, the myeloid lineage transforms and eventually
expands, leading to displacement of the normal stem cell/pro-
genitor compartment.
p42-Deficient AML Is Transplantable in the Absence
of Phenotypic HSCs
The vastly increased ability of p42-deficient myeloid progenitors
to proliferate, combined with the decrease in LSK, CMP, and
GMP populations, indicated a committed myeloid progenitor
as a likely target of transformation. To determine whether the
resulting tumors indeed contained myeloid cells capable of initi-
ating leukemia, L/L-3 BM cells (CD45.2 allotype) containing very
low levels of LSK cells (Figure 5A) were enriched for Mac-1+ cells
by immunomagnetic separation. At this point, LSK cells were
undetectable (data not shown). One hundred thousand such
cells were competitively transplanted into lethally irradiated
CD45.1 recipients, along with 400,000 CD45.1/2 wild-type
(WT) BM cells to provide radioprotection and competition.
Control mice received 100,000 cells from L/+ BM and 400,000
CD45.1/2 competitor BM cells. L/L-transplanted mice devel-
oped leukopenia and anemia (Figure 5B) and became moribund
or died within 9–18 weeks (Figure 5C), whereas no leukemia or
lethality was observed in L/+ transplanted mice. Analysis of
BM and spleen from moribund mice showed that normal hema-
topoiesis was largely displaced by CD45.2 cells that expressed
Mac-1 or c-Kit (Figure 5D) and were devoid of LSK cells
(Figure 5E).
This result was consistent with a non-HSC phenotype of the
LIC. To further address this possibility, we sorted leukemic
L/L-3 and normal L/+ BM cells into four fractions, using a lineage
cocktail without anti-Mac-1 and anti-Gr-1 (Lin*): Lin*Sca-1+
cells (fraction A, containing the HSC compartment), Lin*Mac-
1Sca-1c-Kit+ (fraction B: containing the CMP/GMP/MEP
compartment), Lin*Mac-1+c-Kit+ (fraction C: containing commit-
ted myeloid progenitors), and Lin*Mac-1+c-Kitlo/ (fraction D,
(G) LSK cells sorted from +/+, L/+, and L/L-1 mice (initial plating, 120 cells/dish)
were replated in M3434 medium as in (B). Error bars = SD.
(H) Analysis of the LSK compartment in transformed (L/L-3) mice and +/+ and
L/+ controls. The size of the LSK (right) and Lin-Sca-1-c-Kit+ (left) populations
is shown as a percentage of total BM cells. Results are representative of four
determinations.
(I) Analysis of the myeloid progenitor compartments in transformed (L/L-3)
mice and +/+ and L/+ controls. The size of the CMP, GMP, and MEP popula-
tions is shown as a percentage of total BM cells. Results are representative of
four determinations.Cancer Cell 13, 299–310, April 2008 ª2008 Elsevier Inc. 303
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plantable
(A) Immunophenotype of L/+ and L/L-3 BM used
for transplantation. The percentages of Lin/lo
and LSK cells of total BM cells are indicated.
(B) Analysis of peripheral blood of transplanted
mice 9 weeks after transplantation (L/+ [n = 6],
black bars; L/L-3 [n = 6], gray bars). The numbers
of leukocytes (WBC: total leukocytes; NE: neutro-
phils; LY: lymphocytes; MO: monocytes), red
blood cells (RBC), hematocrit (HCT), and hemo-
globin (HGB) values are shown. Asterisks indicate
significant difference from L/+ controls (*p < 0.05;
**p < 0.001). Error bars = SD.
(C) Kaplan-Meier plot of mice transplanted with
Mac-1-enriched leukemic L/L-3 BM or control
L/+ BM cells (n = 6 for both groups). Significance
of decreased survival of L/L-3 versus L/+ trans-
planted mice is indicated.
(D) BM from L/+ and L/L-3 transplanted mice was
stained with CD45.1-FITC and CD45.2-PE, to
identify donor CD45.2 cells, and with Mac-1-
PerCP and c-Kit-APC, to determine the number
of myeloid cells and c-Kit+ progenitors. Percent-
ages indicate the proportion of gated populations.
(E) Immunophenotype of BM cells of mice trans-
planted with L/+ and L/L BM cells. Cells were
stained with biotinylated lineage cocktail in which
anti-CD45.1-bio was included to eliminate CD45.1
host and CD45.1/2 competitor cells from the Lin/lo
compartment, followed by Sav-PerCP, anti-
Sca-1-PE, and anti-c-Kit-APC. The proportion of
Lin,CD45.1/lo and LSK cells are indicated as per-
centage of the total cell population.containing differentiated myeloid cells) (Figure 6A). Two thousand
cells of each fraction (CD45.2 allotype) were transplanted into
lethally irradiated CD45.1 recipients, along with 250,000 WT
CD45.1/2 competitor cells. Monitoring of peripheral blood chime-
rism showed, as expected, only the HSCs containing fraction A
from L/+ BM engrafted mice (6/6 recipients). In contrast, the
leukemic BM engraftment was observed only in mice trans-
planted with fraction C containing the committed myeloid cells
(Figure 6B). Analysis of CD45.2 PB cells showed multilineage
engraftment in L/+ mice, whereas in L/L-3 transplanted mice,
engraftment was restricted to the myeloid lineage (Figure 6C;
6/6 recipients), consistent with the leukemia-initiating population
being myeloid committed. Analysis of BM from transplanted
mice confirmed that repopulation was restricted to fraction A for
L/+ donors and to fraction C for L/L-3 donors, whereas engraft-
ment of the CD45.1/2 competitor cells was seen in all recipients
(Figure 6D). Also in BM, the L/L-3 fraction C engraftment was
myeloid restricted (Figure 6E), and HSC engraftment (measured
as CD45.2+CD45.1 donor LSK cells) was seen only in the L/+
fraction A-transplanted mice (Figure 6F). Finally, high levels of
Mac-1+c-Kit+ cells (fraction C phenotype) could be retrieved
from L/L-3 fraction C recipients (Figure 6G). These cells gave
rise to malignant disease upon retransplantation (data not shown).304 Cancer Cell 13, 299–310, April 2008 ª2008 Elsevier Inc.Gene Expression Signature of p42-Deficient LIC
The fraction C containing the LIC population was isolated from
three independently transplanted L/L-3 recipients and was com-
pared by gene profiling to normal Mac-1+c-Kit+ progenitors from
L/+ control mice. This provided an expression signature for the
LL-LIC, consisting of both upregulated (388 probe sets) and
downregulated genes (444 probe sets; false discovery rate
[FDR] = 0.01; Table S1). Among these we confirmed upregulation
of the surface antigen CD34 and downregulation of CD24 by flow
cytometric analysis (Figure 7A). Also, the regulation of a number
of potentially relevant genes was confirmed by Q-PCR: Mef2C,
Klf4, Ccnd2 were downregulated in LL-LICs, compared with
normal progenitors, with a similar trend forCcnd1, whereasDdit3
(encoding CHOP, a negative regulator of canonical C/EBPs) and
the antiapoptotic gene Bcl2a1a were upregulated (Figure 7B).
In addition to upregulation of Ddit3, downregulation of Cebpb
was observed, indicating additional dysregulation of the C/EBP
complex.
Of particular interest was the downregulation of Mef2c,
HoxA9, and Meis1 in LL-LIC: these genes are part of the
L-GMP HSC-like signature. Mef2C was demonstrated to be
functionally important for L-GMPs through RNAi knockdown
(Krivtsov et al., 2006), and Hoxa9 and Meis1 are essential for
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Progenitors Initiate p42Knockout Leukemia
(A) Cell sorting strategy used to isolate fractions A
(Lin*Sca-1+), B (Lin*Sca-1c-KithiMac-1), C
(Lin*Sca-1Mac1+c-Kit+), and D (Lin*Sca-
1Mac1+c-Kit) from L/+ (upper panels) and
L/L-3 mice (lower panels).
(B) PB engraftment of donor-derived cells (CD45.2)
12 weeks after competitive transplantation of
23 103 bone marrow cells (CD45.2) from fractions
A, B, C, and D of L/+ or L/L-3 mice with 2.5 3 105
competitor cells (CD45.1/2). Allotypes were deter-
mined by flow cytometry on PB mononuclear cells
using anti-CD45.1-PE and anti-CD45.1-FITC anti-
bodies (n = 5 mice/fraction). **p < 0.001, versus
all other fractions. Error bars = SD.
(C) Representative dot plots of PB from L/+ fraction
A (upper panel) and L/L-3 fraction C (lower panel)
transplanted mice. Contribution of donor-derived
cells (CD45.2) for myeloid cells (Mac-1+), B cells
(B220+), and T cells (CD4/CD8+). Percentages indi-
cate the proportion of gated populations.
(D) BM engraftment of donor-derived cells
(CD45.2) and competitor cells (CD45.1/2) 14
weeks after competitive transplantation of 2 3
103 bone marrow cells (CD45.2) fractions A, B, C,
and D from L/+ or L/L-3 mice with 2.5 3 105 com-
petitor cells (CD45.1/2). Allotypes were deter-
mined by flow cytometry on BM cells using anti-
CD45.1-PE and anti-CD45.2-APC-Cy7 antibodies
(n = 5 mice/fraction). **p < 0.001 and *p < 0.01,
versus all other fractions. Error bars = SD.
(E) Immunophenotype CD45.1CD45.2+ donor
cells L/+ fraction A (upper panel) and L/L-3 fraction
C (lower panel) was determined by staining with
anti-Mac-1-PE-Cy5 and anti-B220-PE to identify
myeloid and B-lineage cells. Percentages indicate
the proportion of gated populations.
(F) The contribution of L/+ fraction A (upper panel)
and L/L fraction C (lower panel) donor cells to the
BM LSK compartment was analyzed. BM cells
were stained with purified lineage cocktail (revealed with CyChrome-conjugated goat anti-rat antibody), Sca-1-PE, and c-kit-APC to determine LSK cells, and
anti-CD45.1-PE-Cy5 and anti-CD45.2-FITC to identify CD45.1CD45.2+ donor cells. Percentages indicate the proportion of total BM cells.
(G) Immunophenotype of BM from L/+ fraction A (upper panel) and L/L-3 fraction C (lower panel) transplanted mice stained with CD45.1-PE and CD45.2-APC-Cy7
to identified donor CD45.2+ cells; BM cells were stained with biotinylated lineage cocktail (without anti-Mac1 and anti-Gr1) in which biotinylated anti-CD45.1 was
included to eliminate CD45.1 host and CD45.1/2 competitor cells from the Lin/lo compartment followed by Sav-PE-Cy5, Sca-1-PE-Cy7, and c-Kit-APC and
Mac-1-FITC to determine myeloid progenitors. Percentages indicate the proportion of gated populations.transformation by MLL fusion proteins (Ayton and Cleary, 2003;
Wong et al., 2007). Their downregulation suggested that the mo-
lecular reprogramming of myeloid progenitors underlying LL-LIC
transformation was distinct from that of the L-GMP. Indeed, of
the 420 probe sets present in the L-GMP/HSC self-renewal
signature, only 25 were present in the LL-LIC upregulated probe
sets, versus 16 in the downregulated probe sets (Table S2), sug-
gesting a limited overlap with the LL-LIC signature. We therefore
proceeded to use the LL-LIC signatures to perform unsupervised
hierarchical clustering of LL-LIC, L-GMP, and normal hemato-
poietic progenitors using our own as well as published gene
expression profiles (Krivtsov et al., 2006). Using the combined
signatures of both up- and downregulated genes from the
LL-LIC profiling, the L-GMP and LL-LIC were found to cocluster
(Figure S7), indicating that the L-GMP gene expression signature
was related to the LL-LIC signature and suggesting the existence
of a common progenitor transformation signature that is notdependent on the underlying initiating mutation. To confirm
this and to identify this putative common signature, we next per-
formed Gene Set Enrichment Analysis (GSEA). This algorithm
may be used in a comparison between two sets of expression
profiles to determine whether a particular expression signature
is enriched or depleted (Subramanian et al., 2005). We used
GSEA to determine whether the L-GMP expression profile was
enriched in genes upregulated in LL-LICs or depleted of genes
downregulated in this population, compared with normal
GMPs. Both were found to be the case (Figure S8). There were
113 LL-LIC upregulated probe sets in enrichment core for
L-GMPs, versus GMP (p < 0.01), and 159 downregulated probe
in depletion core for L-GMPs, versus GMP (p < 0.01). A similar
result was obtained in comparisons with the combined LSK,
CMP, GMP, and MEP expression profiles (data not shown).
Of the 113 probe sets accounting for the core enrichment of
LL-LIC upregulated genes in L-GMP, 23 were shared with theCancer Cell 13, 299–310, April 2008 ª2008 Elsevier Inc. 305
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but limited, overlap between the two. The top 50 probe sets
coenriched in L-GMP and LL-LIC are shown in Table 1.
DISCUSSION
The results presented here support several conclusions. First,
our results genetically validate AML-associated CEBPA muta-
tions as causative of AML and identify the separation of
myeloid lineage commitment from progenitor proliferation con-
trol as a cellular mechanism underlying the oncogenic potential
of mutations affecting C/EBPa. Second, we show that an
endogenous leukemia-initiating mutation present throughout
the hematopoietic hierarchy induces the generation of commit-
ted myeloid LICs. Third, we find that such transformation may
occur with activation of a gene-expression program overlap-
ping that induced by MLL-AF9, but not including Hoxa9,
Mef2c, or Meis1.
C/EBPa p42 Is a Myeloid Tumor Suppressor
The prevalence of CEBPA mutations leading to the specific loss
of p42 in sporadic human AML (Leroy et al., 2005; Nerlov, 2004)
and in the germline of familial AML pedigrees (Sellick et al.,
2005; Smith et al., 2004) strongly indicated a role for such
Figure 7. Profiling of LL-LIC
(A) Surface expression of CD24 and CD34 on Mac1+c-Kit+ progenitors was
measured by flow cytometry on BM from CD45.1/2 recipients transplanted
with L/L-3 fraction C (L/L-LIC) and L/+ fraction A cells (L/+ control) (CD45.2
allotype). The gated population was Lin*-c-Kit+Mac-1+CD45.1CD45.2+.
(B) Quantitative real-time PCR analysis of gene expression in LL-LIC and L/+
fraction C cells. Cells were isolated from mice transplanted as in (A). Measure-
ments are from three individually transplanted recipients, each performed in
triplicate. Error bars indicate SD. *p < 0.05; **p < 0.01. Error bars = SD.306 Cancer Cell 13, 299–310, April 2008 ª2008 Elsevier Inc.mutations in leukemogenesis. However, although complete
inactivation of Cebpa in the hematopoietic system led to the
accumulation of immature blasts in the bone marrow, no malig-
nant disease resulted (Zhang et al., 2004). This is likely the result
of a complete block in myeloid lineage formation, because
GMPs fail to form in the absence of C/EBPa. Indeed, BCR-
ABL, which normally induces transformation of the myeloid
lineage, fails to induce AML in the absence of C/EBPa, but
rather induces erythroleukemia (Wagner et al., 2006). p42-defi-
cient myeloid cells are capable of myeloid lineage commitment,
as evidenced by the formation of GMPs in L/L mice. Further-
more, BRM2 mice normally form GMPs and develop transfor-
mation of the myeloid lineage (Porse et al., 2005). Indeed, the
phenotypic progression observed in L/L mice is similar to that
seen in BRM2 mice, with initial neutropenia (L/L-1, BRM2-A
phenotypes) succeeded by granulocyte hyperproliferation (L/L-2,
BRM2-B phenotypes) and transformation (L/L-3, BRM2-C
phenotypes), and we have shown that the BRM2-A and
BRM2-B phenotypes progress to BRM2-C upon transplantation
(Porse et al., 2005). Because p30 is deficient in E2F repression
(Johansen et al., 2001), these observations are consistent with
loss of C/EBPa-mediated E2F repression being an important
component of the transformation process and being likely to
drive the phenotypic progression, possibly by imposing selec-
tive pressure on the HSC compartment. Thus, selection for
HSCs adapted to increased E2F activity by genetic or epige-
netic means could allow the myeloblast that fail to survive in
the LL-1 phenotype to differentiate, leading to the observed
hyperproliferation of granulocytic cells. The high proliferative
potential of myeloid progenitors in L/L mice is similar to that
observed in BRM2 mice, indicating that the inability of p30 to
repress E2F-dependent transcription also contributes directly
to the increase in progenitor self-renewal capacity seen in the
absence of p42. However, in the case of BRM2 mice, the trans-
formed myeloid cells were not malignant. Overall, these results
indicate that loss or retention of specific C/EBPa functions is
required to induce malignant transformation of the myeloid line-
age and, in particular, that the lineage instructive property of
C/EBPa needs to be maintained for myeloid lineage transforma-
tion to occur and AML to develop. It is therefore of importance
to develop genetically accurate models for CEBPA mutant AML
to obtain clinically relevant mouse models.
The present data demonstrate that a knockin mutation that
mimics the most prevalentCEBPAmutation observed in patients
with AML causes myeloid leukemia with full penetrance in
a mouse model. Our results provide direct genetic verification
of the etiological relevance of these mutations and also demon-
strate that the tumor suppressor activity of C/EBPa resides in the
42 kDa translational isoform. At the cellular level, our results
show that efficient transformation of the granulocyte lineage
observed in the absence of p42 is due to efficient p30-mediated
bypass of the C/EBPa-dependent CMP-GMP transition, cou-
pled with loss of proliferation control of the downstream myeloid
progenitor population. In AML, specific loss of p42 may therefore
be a means to circumnavigate the C/EBPa-controlled coupling
of lineage commitment and proliferation control during myeloid
differentiation, leading to the formation of progenitors with
unchecked proliferative capacity and the ability to undergo
transformation.
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Probe Set Gene Symbol Rank in Gene List Rank Metric Score Running ES Self-Renewal Signature
1425180_at SGIP1 6 8.092350006 0.02575028
1418472_at ASPA 8 7.616382122 0.0501929
1425470_at NA 10 7.364430904 0.07382548 yes
1425181_at SGIP1 12 7.132127762 0.096711196
1419609_at CCR1 15 6.842639923 0.11862166
1424186_at CCDC80 19 6.723652363 0.14010505
1450764_at AOAH 30 5.84819603 0.15846215
1452050_at CAMK1D 35 5.585491657 0.17624177 yes
1419127_at NPY 36 5.456165314 0.19378369
1449924_at PRG3 38 5.318623543 0.21083887
1421681_at NRG4 40 5.198602676 0.22750817
1417614_at CKM 45 5.031453133 0.24350652
1425471_x_at NA 49 4.875173092 0.25904694 yes
1451161_a_at EMR1 50 4.84481287 0.2746233
1449819_at DMC1 52 4.79646492 0.28999972
1418907_at NA 59 4.535372734 0.3043141
1420335_at DMC1 65 4.377119541 0.3181642
1416013_at PLD3 79 4.21172142 0.33112636 yes
1437752_at LIN28 94 3.97721839 0.34329006
1426864_a_at NCAM1 106 3.80211997 0.3550244
1450109_s_at ABCC2 118 3.669750929 0.36633313
1426865_a_at NCAM1 126 3.627708912 0.37768477
1448162_at VCAM1 128 3.613016605 0.38925633
1425451_s_at CHI3L3/CHI3L4 129 3.591151476 0.4008021
1451972_at GLCCI1 137 3.515051842 0.41179156
1419610_at CCR1 138 3.503375053 0.42305514
1460719_a_at P2RX1 139 3.501185894 0.43431166 yes
1448050_s_at MAP4K4 140 3.469474077 0.44546625 yes
1454628_at A930037G23RIK 141 3.46923852 0.45662007
1460252_s_at ZNF35 147 3.374240637 0.46724585
1456195_x_at ITGB5 150 3.332718134 0.4778717 yes
1417605_s_at CAMK1 153 3.282420874 0.48833585 yes
1422760_at PADI4 203 2.766919374 0.4950501 yes
1423702_at H1F0 213 2.702160597 0.503337
1425407_s_at CLEC4A2/4B 225 2.626604557 0.511292
1422013_at CLEC4A2 237 2.562724113 0.51904154
1419764_at CHI3L3 261 2.355534792 0.5255908
1418252_at PADI2 268 2.326452494 0.5328033
1427932_s_at 1200003I10RIK 295 2.189368725 0.5386847
1419004_s_at BCL2A1A/BCL2A1B 296 2.185925722 0.5457126
1422818_at NEDD9 298 2.175006866 0.5526608
1425548_a_at LST1 299 2.174248934 0.5596512 yes
1415866_at UNC45A 316 2.122360468 0.56576234
1424975_at SIGLECF 320 2.106169701 0.5724003
1425113_x_at NA 326 2.077837706 0.578858
1416759_at MICAL1 330 2.064893246 0.5853632
1454758_a_at TSC22D1 346 1.989614367 0.59109217
1422532_at XPC 362 1.923462152 0.5966084 yes
1450522_a_at H1F0 366 1.910332084 0.60261667 yes
1452657_at AP1S2 371 1.906752586 0.6085689Cancer Cell 13, 299–310, April 2008 ª2008 Elsevier Inc. 307
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The derivation of AML LICs from committed progenitors through
transduction of AML-derived translocation products provided
proof-of-principle that acquisition of leukemogenic potential
may occur in a progenitor with limited proliferative potential.
However, the use of viral transduction raises the issue of whether
overexpression or ex vivo target cell selection influenced the
results. By using a knockin approach, we have achieved the
introduction of a common leukemogenic mutation in a manner
that efficiently interrogates the entire hematopoietic hierarchy
in its normal in vivo state, and where the oncogenic protein is
expressed from its endogenous promoter. This led to the gener-
ation of LICs with a Mac1+c-Kit+ myeloid-committed immuno-
phenotype that gave rise exclusively to myeloid cells in irradiated
recipients, identifying them as transformed myeloid-restricted
progenitor cells. These results indicate a propensity of Cebpa
mutations to act on committed myeloid progenitors in vivo. As
noted above, in studies of patients with AML patients who
carried CEBPA mutations and who underwent complete remis-
sion and subsequent relapse, the initially observed CEBPA mu-
tant alleles were almost uniformly present also in the relapse
AML cells (Lin et al., 2005; Tiesmeier et al., 2003), indicating
that CEBPA mutations are very early, possibly preleukemic,
events in AML progression. Thus, although the nature of second-
ary genetic or epigenetic events contributing to cellular transfor-
mation in the L/L-3 mice remains to be determined, it is likely that
our genetic model reflects the sequence of events normally
occurring in human AML. By gene profiling of the LL-LIC popu-
lation, we identified gene subsets that were consistently up-
and downregulated in the transformed progenitors, and these
genes were significantly enriched also in MLL-AF9-transformed
L-GMPs. An important part of the transformation signature may
therefore be determined by the target cell and the molecular
properties of the differentiation program that has to be overrid-
den by unlimited self-renewal. In contrast, overlap with the
HSC-associated self-renewal signature was more limited; in
particular, Mef2c, Hoxa9, and Meis1 were all downregulated,
suggesting that, although clearly important in the case of MLL-
AF9-induced transformation, there is not a general requirement
for their upregulation during progenitor transformation. This
observation is consistent with upregulation of these genes in
human AML being limited to those leukemias containing MLL
translocations (Krivtsov et al., 2006). Conversely, we observed
additional deregulation of the C/EBP complex (i.e., upregulation
of Ddit3/Cebpz and downregulation of Cebpb), which is a trait
not shared with the MLL-AF9-transformed progenitors. Thus,
common and initiator mutation-specific traits may coexist in
leukemic progenitor populations, and both may be required for
transformed to occur. It is interesting that the LIC activity was
detected in the Mac-1+c-Kit+ fraction C, but not in the
Mac-1/loc-Kit+ fraction B. This could be due to either lower fre-
quency of LICs in the latter population or a role for Mac-1 or308 Cancer Cell 13, 299–310, April 2008 ª2008 Elsevier Inc.other adhesion molecules differentially expressed on these
populations in homing of LICs to an appropriate location. This
is currently being investigated.
How do we reconcile the data obtained in murine genetic and
viral transduction experiments defining LICs as bipotent or com-
mitted myeloid progenitors with those obtained by NOD/SCID
transplantation of human AML cells, where LICs were cells
with a CD34+CD38 phenotype, similar to that of normal SCID-
repopulating HSCs (Bonnet and Dick, 1997; Lapidot et al.,
1994)? First, it should be noted that the murine model system
is able to model AML based in the LSK compartment, as exem-
plified by the disease observed in mice carrying knockdown
mutations in the Sfpi1 gene, which encodes the PU.1 transcrip-
tion factor (Steidl et al., 2006). Second, 30%–50% of human AML
cases do not engraft in NOD/SCID mice, and the capacity to
engraft has been found to correlate with adverse prognosis
(Monaco et al., 2004; Pearce et al., 2006). This would be consis-
tent with a distinct type of LICs, which are more responsive to
current treatment protocols but are not able to engraft in the
current NOD/SCID model, being present in patients with good
prognosis. A self-renewing and proliferative myeloid progenitor
would be a candidate for such an LIC. This is a possibility that
is currently being tested and that could have a significant impact
on AML treatment should it become feasible to prospectively
identify distinct types of patient LICs.
EXPERIMENTAL PROCEDURES
Generation and Maintenance of Cebpa p42 Knockout Mice
p42 knockout mice were generated by standard techniques. Details are
provided in the Supplemental Experimental Procedures. Mice were main-
tained on standard chow under specific pathogen free conditions on a 75%
C57BL/6, 25% 129/Ola background for all experiments, and littermates
were used as controls. Mice were monitored by peripheral blood analysis
and were considered moribund when they were severely anemic; this in all
cases correlated with the presence of disseminated disease. Animal experi-
ments were approved by the EMBL Monterotondo Ethical Committee and
were performed according to EMBL institutional and Italian national guide-
lines.
Blood and Hematopoietic Tissue Analysis
Mice were tail bled, and peripheral blood counts were performed using a
Hemavet 950 (Drew Scientific) calibrated for mouse blood. Flow cytometry
was performed as described elsewhere (Kirstetter et al., 2006; Porse et al.,
2005). For cell cycle analysis, BrdU incorporation was detected by flow cytom-
etry using the BrdU Flow Kit (PharMingen), according to the manufacturer’s
instructions. BrdU labeling was for 2 hr before death. Differential counts
were performed as described elsewhere (Porse et al., 2005).
Histology
Sections of liver or adipose tissue were prepared as described elsewhere
(Porse et al., 2001) and were stained with hematoxylin-eosin or were used
for immunohistochemistry using rabbit anti-MPO (A0398; DAKO) or rabbit
anti-NGAL (Kjeldsen et al., 1996) as primary antibody. Binding of primary
antibodies was detected using an Envision+ HRP (DAB) detection kit (DAKO),The table shows the top 50 probe sets providing the core enrichment of LL-LIC upregulated genes in L-GMPs (six samples), compared with normal
GMP (four samples) (Krivtsov et al., 2006). All MOE430A probe sets (22691) were ranked according to their expression in L-GMP versus normal pro-
genitors using the GSEA algorithm. The probe sets shown are the 50 highest contributors to the positive enrichment score (leading edge). The rank
of the probe sets (in L-GMP/GMP comparison), the running enrichment score (ES), and the probe sets present in the MLL-AF9 and HSC-derived
self-renewal signature (Krivtsov et al., 2006) are indicated. NA, not annotated.
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were counterstained with hematoxylin.
Tissue Culture and Colony Assays
Colony assays were performed as described elsewhere (Porse et al., 2005).
Immortalized L/L cells were grown in DMEM plus 10% FCS (Invitrogen)
supplemented with 50 ng/ml SCF, 10 ng/ml IL-6, and 10 ng/ml IL-3 (Sigma).
For analysis of factor dependence, 5 3 103 cells were washed and plated in
the same medium, omitting the indicated factor, and live cells were counted
after 3 and 6 days.
Western Blotting
Nuclear lysate was prepared from approximately 200 mg of liver by homoge-
nization in 15 ml of hypotonic buffer (10 mM HEPES [pH 7.9], 1.5 mM MgCl2,
10 mM KCl, and 0.5 mM DTT) using a Dounce homogenizer (B-type pestle,
10 strokes); liver was left on ice for 10 min to allow any clumps to settle. Nuclei
were collected by centrifugation (20 min, 450 g), were resuspended in 300 ml of
PBS, and were lysed by addition of 300 ml of SDS loading buffer (250 mM
Tris-Cl [pH 6.8], 40% sucrose, 12% SDS, and 6% b-mercaptoethanol) and
boiling. Western blotting was performed as described elsewhere (Porse
et al., 2001) using 14AA rabbit anti-C/EBPa antibody (sc-61; Santa Cruz Bio-
technology), mouse antitubulin (T9026; Sigma), and mouse anti-b-actin
(A4700; Sigma).
FACS Analysis, Cell Separation, and Cell Sorting
Antibodies were obtained from PharMingen or eBioscience. Flow cytometric
analysis was performed as described elsewhere (Kirstetter et al., 2006; Porse
et al., 2005). Magnetic-activated cell separation (MACS; Miltenyi Biotech) was
performed by labeling with biotinylated anti-Mac-1 (CD11b; clone M1/70) and
streptavidin coupling to paramagnetic beads (Miltenyi Biotec), as recommen-
ded by the manufacturer. For cell sorting, BM cells were subjected to immuno-
magnetic-based pre-enrichment using a biotinylated-conjugated lineage
cocktail containing CD4 (RM4-5), CD8 (53-6), B220 (RA3-6B2), CD5 (53-7.3),
and Ter119 (Ly-76). Lin* cells were incubated with Sav-PE-Cy5, Sca-1-PE-
Cy7, c-Kit-APC, and Mac-1-FITC. A FACSAria cell sorter (Becton Dickinson)
was used for sorting fractions A, B, C, and D from L/+ and L/L-3 mice. LSK,
GMP, and MEP staining was performed as described elsewhere (Kirstetter
et al., 2006). Sorting was performed using a FACSAria cell sorter.
SKY
For SKY, primary tumor cells were cultured in M3434 medium and were
processed as described elsewhere (Schrock et al., 1996).
Bone Marrow Transplantation
Recipient mice were exposed to 5.5 Gy total-body X-irradiation 6 hr before BM
transplantation. For transplantation of magnetically enriched cells, CD45.1/2
recipients received 4 3 105 C57BL/6-CD45.1 competitor total BM cells and
13 105 CD45.2 cells from L/+ or L/L mice. For transplantation of sorted cells,
CD45.1 recipients received 2.53 105 CD45.1/2 competitor total BM cells with
2 3 103 CD45.2 cells from fraction A, B, C, or D from L/+ or L/L-3 mice.
Determination of donor/competitor contribution and lineage contribution
was determined as described elsewhere (Kirstetter et al., 2006).
Microarray Analysis and Statistical Analysis
For details of microarray data analysis, see the Supplemental Experimental
Procedures.
GSEA was performed as described elsewhere (Subramanian et al., 2005),
using the GSEA 2.0 algorithm (http://www.broad.mit.edu/gsea). Ranked
expression lists of up- or downregulated genes derived from the analysis of
LL-LIC and control arrays were used as gene sets, and their enrichment was
tested in a data set consisting of arrays from L-GMP and GMP samples
(Krivtsov et al., 2006), where genes were ranked on the basis of Student’s
t test. Statistical significance was determined using Student’s t test, except
for significance of differences in survival, where the log-rank test was used.ACCESSION NUMBERS
The microarray data generated in this study are deposited in the European
Bioinformatics Institute ArrayExpress database (http://www.ebi.ac.uk/
arrayexpress) with the accession number E-MEXP-1444.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, eight
supplemental figures, and two supplemental tables and can be found with this
article online at http://www.cancercell.org/cgi/content/full/13/4/299/DC1/.
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